Angeion Corporation Enters Agreement
with Garmin International

Angeion's New Leaf Profile Now Downloadable to Garmin's Forerunner® 305 GPS

SAINT PAUL, Minn. (March 29, 2007) — Angeion Corporation (NASDAQ: ANGN) announced today an agreement with Garmin International enabling integration of Angeion’s New Leaf Active Metabolic Training™ with Garmin’s Forerunner 305 GPS fitness device.

Now, users can download their unique New Leaf Active Metabolic Training profile to their Garmin Forerunner® 305 via the Internet. The Forerunner 305 can then audibly and visually guide users through their exercise based on personalized heart rate zones from their metabolic profile to make every workout count. The New Leaf download includes measured calories, metabolic training zones, and up to 12 weeks of workouts.

The Garmin Forerunner 305 is a highly integrated GPS fitness device that monitors heart rate and calories burned as well as time, speed, distance while exercising either indoors or outdoors.

New Leaf Active Metabolic Training begins with a 10-15 minute personal metabolic assessment that analyzes the exchange of oxygen and carbon dioxide in the breath along with heart rate over a range of exercise intensities. The assessment results in actual measured calories, fuel efficiency (fat utilization), anaerobic threshold, and peak oxygen consumption. This snapshot of metabolism serves as the basis for designing successful exercise programs for weight control, fitness, or athletic performance goals. New Leaf assessments are available from a variety of health, fitness, and performance centers throughout North America and in select international markets. For the nearest New Leaf site by zip code, see www.newleaffitness.com.

“This agreement between Angeion and Garmin is a natural fit,” commented Rod Young, President and CEO of Angeion Corporation. “Garmin is widely recognized for making GPS technology available for everyday use by active people around the world. Adding New Leaf metabolic training technology to the Forerunner creates a unique, personalized tool for everyone that exercises.”

“We are pleased to offer the New Leaf Active Metabolic capability to Forerunner 305 owners,” said Dan Bartel, Garmin’s vice president of worldwide sales. “Combining the Forerunner with New Leaf Active Metabolic Training helps people achieve their fitness goals faster as they exercise smarter, not harder.”

Garmin and Angeion New Leaf will be demonstrating the benefits of training with the Forerunner 305 and New Leaf at the 26th Annual International Health, Racquet and Sportsclub Association (IHRSA) convention, March 28-31, 2007, in San Francisco, California (booth 233).

About Garmin International, Inc.

Garmin International Inc. is a member of the Garmin Ltd. group of companies, which designs and
manufactures navigation, communication and information devices - most of which are enabled by GPS technology. Garmin is a leader in the general aviation and consumer GPS markets and its products serve aviation, marine, outdoor recreation, automotive, wireless and OEM applications. Garmin and Forerunner are registered trademarks of Garmin Ltd. or its subsidiaries.

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999.
Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Our results may differ materially depending on a variety of factors, including: (i) our ability to successfully operate our business, including our ability to develop, improve, and update our cardiorespiratory diagnostic products, (ii) our ability to ensure constant margins for products in light of fluctuating revenues from our clinical research customers, (iii) our ability to effectively manufacture and ship our products in required quantities to meet customer demands, (iv) our ability to successfully defend the Company from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products, (v) our ability to protect our intellectual property, (vi) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures, and (vii) our dependence on third-party vendors. Because actual results may differ, shareholders and prospective investors are cautioned not to place undue reliance on such forward-looking statements which are qualified in their entirety by the risk factors referred to above and the other risk factors that are described from time to time in Angeion's Securities and Exchange Commission reports, including but not limited to the Annual Report on Form 10-KSB for the year ended October 31, 2006, and subsequently filed reports.

###